期刊
CNS DRUGS
卷 29, 期 2, 页码 83-89出版社
ADIS INT LTD
DOI: 10.1007/s40263-014-0221-z
关键词
-
资金
- USWorld Meds
- HSG
- Lundbeck Dystonia Coalition
- ACADIA
- Auspex
- Lundbeck
- UCB Pharma
- TEVA
- Merz
- Avanir
Current research shows that apomorphine is an effective treatment for symptoms of Parkinson's Disease (PD). The highly lipophilic structure allows apomorphine to cross cell membranes rapidly, leading to the rapid onset of action for on/off symptoms of PD. The use of apomorphine was limited in the past due to peripheral side effects, but with the advent of better delivery systems and medications to control side effects, apomorphine is better tolerated and more widely in use. The major delivery systems are continuous subcutaneous infusions and intermittent subcutaneous injections, but other delivery routes are under investigation. The purpose of this article is to discuss the current use of apomorphine, the current delivery systems and to discuss future research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据